Adaptive Biotechnologies Corporation Stock
Equities
ADPT
US00650F1093
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.45 USD | -4.43% | +0.29% | -29.59% |
Financials (USD)
Sales 2024 * | 170M | Sales 2025 * | 209M | Capitalization | 508M |
---|---|---|---|---|---|
Net income 2024 * | -189M | Net income 2025 * | -149M | EV / Sales 2024 * | 2.91 x |
Net cash position 2024 * | 14.91M | Net cash position 2025 * | 7.88M | EV / Sales 2025 * | 2.4 x |
P/E ratio 2024 * |
-2.68
x | P/E ratio 2025 * |
-3.27
x | Employees | 709 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.9% |
Latest transcript on Adaptive Biotechnologies Corporation
1 day | -4.43% | ||
1 week | +0.29% | ||
1 month | +31.68% | ||
3 months | -16.06% | ||
6 months | -21.23% | ||
Current year | -29.59% |
Managers | Title | Age | Since |
---|---|---|---|
Harlan Robins
FOU | Founder | 51 | 09-09-07 |
Chad Robins
CEO | Chief Executive Officer | 49 | 09-09-07 |
Kyle Piskel
DFI | Director of Finance/CFO | 40 | 21-10-27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Hershberg
BRD | Director/Board Member | 61 | 13-01-31 |
Peter Neupert
BRD | Director/Board Member | 68 | 13-12-31 |
Michael Pellini
BRD | Director/Board Member | 58 | 18-02-12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.68% | 0 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 3.45 | -4.43% | 4,226,315 |
24-05-30 | 3.61 | +0.84% | 1,053,529 |
24-05-29 | 3.58 | -1.92% | 1,950,485 |
24-05-28 | 3.65 | +6.10% | 863,980 |
24-05-24 | 3.44 | -0.29% | 847,516 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.59% | 508M | |
-38.56% | 8.39B | |
+0.18% | 3.32B | |
+9.29% | 2.49B | |
-18.21% | 2.06B | |
-24.57% | 1.59B | |
+32.37% | 1.15B | |
-7.64% | 704M | |
+8.42% | 678M | |
-6.56% | 273M |
- Stock Market
- Equities
- ADPT Stock